Biosynthesis of Drug Metabolites and Quantitation Using NMR Spectroscopy for Use in Pharmacologic and Drug Metabolism Studies

被引:40
作者
Walker, Gregory S. [1 ]
Bauman, Jonathan N. [1 ]
Ryder, Tim F. [1 ]
Smith, Evan B. [1 ]
Spracklin, Douglas K. [1 ]
Obach, R. Scott [1 ]
机构
[1] Pfizer Inc, Biotransformat Grp, Pharmacokinet Dynam & Metab, Groton, CT 06340 USA
关键词
DISCOVERY;
D O I
10.1124/dmd.114.059204
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The contribution of drug metabolites to the pharmacologic and toxicologic activity of a drug can be important; however, for a variety of reasons metabolites can frequently be difficult to synthesize. To meet the need of having samples of drug metabolites for further study, we have developed biosynthetic methods coupled with quantitative NMR spectroscopy (qNMR) to generate solutions of metabolites of known structure and concentration. These quantitative samples can be used in a variety of ways when a synthetic sample is unavailable, including pharmacologic assays, standards for in vitro work to help establish clearance pathways, and/or as analytical standards for bioanalytical work to ascertain exposure, among others. We illustrate five examples of metabolite biosynthesis and qNMR. The types of metabolites include one glucuronide and four oxidative products. Concentrations of the isolated metabolite stock solutions ranged from 0.048 to 8.3 mM, with volumes from approximately 0.04 to 0.150 ml in hexadeutarated dimethylsulfoxide. These specific quantified isolates were used as standards in the drug discovery setting as substrates in pharmacology assays, for bioanalytical assays to establish exposure, and in variety of routine absorption, distribution, metabolism, and excretion assays, such as protein binding and determining blood-to-plasma ratios. The methods used to generate these materials are described in detail with the objective that these methods can be generally used for metabolite biosynthesis and isolation.
引用
收藏
页码:1627 / 1639
页数:13
相关论文
共 17 条
[1]   Drug metabolites in safety testing [J].
Baillie, TA ;
Cayen, MN ;
Fouda, H ;
Gerson, RJ ;
Green, JD ;
Grossman, SJ ;
Klunk, LJ ;
LeBlanc, B ;
Perkins, DG ;
Shipley, LA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) :188-196
[2]   Biomimetic chemical catalysts in the oxidative activation of drugs [J].
Bernadou, J ;
Meunier, B .
ADVANCED SYNTHESIS & CATALYSIS, 2004, 346 (2-3) :171-184
[3]   Nuclear Magnetic Resonance Spectroscopy as a Quantitative Tool To Determine the Concentrations of Biologically Produced Metabolites: Implications in Metabolites in Safety Testing [J].
Espina, Robert ;
Yu, Linning ;
Wang, Jianyao ;
Tong, Zeen ;
Vashishtha, Sarvesh ;
Talaat, Rasmy ;
Scatina, JoAnn ;
Mutlib, Abdul .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :299-310
[4]  
Helal CJ, 2012, European Patent Office Application, Patent No. [WO2012168817 A1, 2012168817]
[5]  
Li W, 2009, BIOCATAL PHARM IND, P183
[6]   Validation of quantitative NMR [J].
Malz, F ;
Jancke, H .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 38 (05) :813-823
[7]  
Manual Bruker, 2012, ERETIC 2 US GUID PRE
[8]   Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy [J].
Obach, R. Scott .
PHARMACOLOGICAL REVIEWS, 2013, 65 (02) :578-640
[9]  
Parkinson A., 2013, Chapter 6: Biotransformation of Xenobiotics, Casarett Doull's Toxicology, The Basic Science of Poisons, V8th, P185
[10]   Quantitative 1H NMR. Development and Potential of an Analytical Method: An Update [J].
Pauli, Guido F. ;
Goedecke, Tanja ;
Jaki, Birgit U. ;
Lankin, David C. .
JOURNAL OF NATURAL PRODUCTS, 2012, 75 (04) :834-851